Study wrapper · #1240
The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
Editor's note
The mechanistic case for GHK-Cu is unusually well developed for a cosmetic peptide, but the clinical base is two trials against 18 preclinical papers, and formulations, doses, and delivery methods vary widely between them. That imbalance is the story: readers should regard the collagen and matrix findings as biologically plausible and the human effect sizes as provisional. Anyone comparing topical products will find the delivery-system data more decision-relevant than the peptide concentration on the label.
Plain-language abstract
Researchers systematically searched the literature for evidence on GHK-Cu, the copper-binding tripeptide widely used in cosmetic and aesthetic formulations, and found 20 studies - 18 preclinical and only 2 randomized controlled trials. The laboratory and animal work consistently showed GHK-Cu increasing type I collagen and glycosaminoglycan production, modulating matrix metalloproteinase activity, encouraging new blood vessel formation, and lowering inflammatory signals including TGF-beta and IL-6. The two human trials reported better patient-reported satisfaction after laser resurfacing and measurable reductions in wrinkle volume and depth versus controls. Delivery matters: microneedle and liposomal systems substantially improved how much peptide crossed the skin barrier.